We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
19
Oct 2026
Better electronic health (e-health) literacy actively drives young adult patients into doctors' offices rather than replacing professional consultations with self-treatment.
19
Oct 2026
A novel study has found that increases in risk-taking behavior in people with mild to moderate alcohol use disorder (AUD) precede increases in alcohol consumption, not vice versa.
19
Oct 2026
Mitochondrial serine catabolic pathway (MSCP), also called serine, glycine, and one-carbon metabolism, is essential for cancer cells to produce amino acids, one-carbon units, and reducing equivalents.
19
Oct 2026
Losartan, a drug commonly prescribed for high blood pressure, boosts brown adipose tissue or "brown fat" activity and enhances its metabolism, according to a preclinical study by Weill Cornell Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center researchers.